#bleedingdisorder — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #bleedingdisorder, aggregated by home.social.
-
Sheffield student believed to be fastest to run a marathon with a bleeding disorder
A Sheffield University student ran the London Marathon in 2:47:46 last weekend, breaking the record for the fastest…
#Sheffield #UnitedKingdom #UK #GB #England #Headlines #News #Europe #EU #bleedingdisorder #Britain #GreatBritain #haemophilia #LondonMarathon #running #sheffield #UniversityofSheffield
https://www.europesays.com/uk/932283/ -
https://www.europesays.com/uk/932283/ Sheffield student believed to be fastest to run a marathon with a bleeding disorder #BleedingDisorder #Britain #England #GreatBritain #haemophilia #LondonMarathon #running #sheffield #UK #UnitedKingdom #UniversityOfSheffield
-
https://www.europesays.com/ie/202237/ Experimental drug engasertib shows promise for treating inherited bleeding disorder #bleeding #BleedingDisorder #blood #BloodVessels #Brain #BrainHemorrhage #Chronic #Efficacy #Éire #Frequency #Health #Heart #HeartFailure #HereditaryHemorrhagicTelangiectasia #IE #Ireland #Liver #Lungs #medicine #Nosebleed #Placebo #Research #Stroke #Therapeutics #Vascular
-
Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Teamhttps://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/
-
Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Teamhttps://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/
-
Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Teamhttps://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/
-
Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Teamhttps://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/
-
Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Teamhttps://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/